{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:13:48Z","timestamp":1772586828159,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T00:00:00Z","timestamp":1424131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.vaccine.2014.07.062","type":"journal-article","created":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T06:30:07Z","timestamp":1406701807000},"page":"2189-2195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years"],"prefix":"10.1016","volume":"33","author":[{"given":"Olivier","family":"Godeaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Izurieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamadou","family":"Dram\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.07.062_bib0005","series-title":"Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.vaccine.2014.07.062_bib0010","series-title":"Pandemic influenza vaccine manufacturing process and timeline","author":"World Health Organization","year":"2013"},{"issue":"7101","key":"10.1016\/j.vaccine.2014.07.062_bib0015","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2014.07.062_bib0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(08)70232-9","article-title":"Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans","volume":"8","author":"Jennings","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2014.07.062_bib0025","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/14712590903066695","article-title":"Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data","volume":"9","author":"Leroux-Roels","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2014.07.062_bib0030","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2014.07.062_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A \u2013 adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2014.07.062_bib0040","series-title":"FDA approves first adjuvanted vaccine for prevention of H5N1 avian influenza","author":"Food and Drug Administration","year":"2013"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.07.062_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virusres.2004.02.029","article-title":"Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use","volume":"103","author":"Hehme","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2014.07.062_bib0050","series-title":"Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance.","first-page":"B17","author":"Kendal","year":"1982"},{"issue":"4","key":"10.1016\/j.vaccine.2014.07.062_bib0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.07.062_bib0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","article-title":"Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A\/Duck\/Singapore\/97 vaccine","volume":"103","author":"Stephenson","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2014.07.062_bib0065","series-title":"Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research","year":"2007"},{"key":"10.1016\/j.vaccine.2014.07.062_bib0070","series-title":"CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine","author":"European Medicines Agency, European Committee for Proprietary Medicinal Products","year":"2009"},{"issue":"12","key":"10.1016\/j.vaccine.2014.07.062_bib0075","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"issue":"9587","key":"10.1016\/j.vaccine.2014.07.062_bib0080","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.07.062_bib0085","series-title":"Options for the design and financing of an H5N1 vaccine stockpile: key findings and study methodology","author":"World Health Organization","year":"2013"},{"issue":"8","key":"10.1016\/j.vaccine.2014.07.062_bib0090","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/infdis\/jiq174","article-title":"Immunogenicity profile of a 3.75-mug hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial","volume":"203","author":"Heijmans","year":"2011","journal-title":"J Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2014.07.062_bib0095","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.vaccine.2008.02.068","article-title":"Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial","volume":"26","author":"Rumke","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14010147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T19:08:57Z","timestamp":1598123337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14010147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":19,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0264410X14010147"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}